Opinion|Videos|July 16, 2026

Navigating Dosing Frequency With Revumenib and Ziftomenib

Compare revimumab and ziftomib dosing, food rules, tablet crushing, PPI interactions and half-life—key counseling tips to boost patient adherence.

In this episode, Ali discusses the clinical implications of twice-daily versus once-daily dosing in patients with relapsed/refractory AML who are frequently monitored in clinic. He explains how half-life differences impact differentiation syndrome management, toxicity offset, and practical adherence counseling.

Latest CME